<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014569</url>
  </required_header>
  <id_info>
    <org_study_id>RMC018718ctil</org_study_id>
    <nct_id>NCT04014569</nct_id>
  </id_info>
  <brief_title>Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational &amp; Proof of Concept Study</brief_title>
  <official_title>Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational &amp; Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DreaMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MDI (Multiple Daily Injections) plus SMBG |(Self Monitoring Blood Glucose) Advisor (MPSA)&#xD;
      is a software product that is designed to assist in insulin dosage decision making for&#xD;
      subjects with T1DM using multiple daily injection and SMBG.&#xD;
&#xD;
      The study will focus on the development, validation and eventually testing of the MPSA&#xD;
      algorithm use. The major objective of the project is to develop an algorithm that will be&#xD;
      able to optimize treatment plan parameters of MDI patients who use SMBG as glucose monitoring&#xD;
      method. The clinical study has two segments. Segment A is an observational study needed for&#xD;
      the development of the algorithm (this segment was already completed at the time of the&#xD;
      registration) and Segment B is a proof of concept interventional study to validate the&#xD;
      algorithm's Safety and Efficacy.&#xD;
&#xD;
      Up to 20 patients using MDI and SMBG or Flash Glucose Monitoring (FGM) without using glucose&#xD;
      trends will be enrolled to this proof of concept study. The study will evaluate the algorithm&#xD;
      use for a period of 11 weeks. Post screening, patients will undergo a two weeks run-in period&#xD;
      while using MDI and SMBG or FGM (patients that do not use FGM will be provided with blinded&#xD;
      Libre Flash to be used during the run-in period and 2 weeks prior to arriving to end of study&#xD;
      visit). Then, patients will undergo insulin treatment plan changes every week for 7 weeks. At&#xD;
      the first 3 weeks insulin dose adjustments will be done for basal insulin dose only, week 4&#xD;
      will be without changes, and in the next 3 weeks the carbohydrate ratio will be amended. No&#xD;
      recommendations will be given during the last two weeks of the study. These two weeks will be&#xD;
      used for data analysis. Each recommendation of the Advisor will be approved by a physician&#xD;
      before implementation. Glucose outcomes will be evaluated comparing the two weeks run-in&#xD;
      period to the last two weeks of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigators decision&#xD;
  </why_stopped>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of sensor glucose readings within range of 70-180 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of sensor glucose readings below 54 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Hypoglycemia events</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic Ketoacidosis events</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings below 70 mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings below 50mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings above 180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of sensor glucose readings above 250mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of unexplained hyperglycemic events</measure>
    <time_frame>Final visit (day42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area above the curve of 180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area above the curve &gt;180mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve of 70mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the curve &lt;70mg/dl</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean sensor blood glucose</measure>
    <time_frame>Final visit (day42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glucose variability measured by SD (standard deviation)</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in settings per patient</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of recommendations for changes in setting per iteration</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of physician override advisor recommendations</measure>
    <time_frame>Final visit (day 42)</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Multiple Daily Injections</condition>
  <arm_group>
    <arm_group_label>MPSA Algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin dosing will be adjusted using the MPSA algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MPSA Algorithm</intervention_name>
    <description>Insulin dosing will be adjusted using the MPSA Algorithm</description>
    <arm_group_label>MPSA Algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented T1D for at least 1 year prior to study enrolment&#xD;
&#xD;
          -  Subjects aged ≥ 14 years and up to 30 years&#xD;
&#xD;
          -  A1c at inclusion ≥ 7 % and ≤ 10%&#xD;
&#xD;
          -  Using MDI of Basal/bolus therapy - basal insulin either Glargine/Lantus or Tregludec&#xD;
             insulin and bolus short acting insulin analogs either aspart/Novorapid or&#xD;
             Lispro/Humalog&#xD;
&#xD;
          -  Using SMBG or flash glucose monitoring (FGM/Libre) without using glucose trends&#xD;
&#xD;
          -  BMI SDS - below the 97th percentile for age&#xD;
&#xD;
          -  Subjects willing to follow study instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An episode of diabetic keto-acidosis within the month prior to study entry and/or&#xD;
             severe hypoglycemia resulting in seizure or loss of consciousness in the month prior&#xD;
             to enrolment&#xD;
&#xD;
          -  Concomitant diseases/ treatment that influence metabolic control or any significant&#xD;
             diseases /conditions including psychiatric disorders and substance abuse that in the&#xD;
             opinion of the investigator is likely to affect the subject's ability to complete the&#xD;
             study or compromise patient's safety&#xD;
&#xD;
          -  Participation in any other interventional study&#xD;
&#xD;
          -  Known or suspected allergy to trial products&#xD;
&#xD;
          -  Female subject who is pregnant or planning to become pregnant within the planned study&#xD;
             duration&#xD;
&#xD;
          -  Subject needs to travel by air during the study duration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Schnider children medical center</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

